share_log

HAVN Life Closes First Tranche Of July Financing By ABO, Details On Amendments And Debt Shares Issuance

HAVN Life Closes First Tranche Of July Financing By ABO, Details On Amendments And Debt Shares Issuance

HAVN Life完成ABO 7月第一批融资,修订细节和债务股份发行
Benzinga Real-time News ·  2022/08/19 16:06
Biotech psychedelics company HAVN Life Sciences Inc. (OTC:HAVLF) recently closed the initial tranche of its financing pact with innovative fund Alpha Blue Ocean ("ABO"), previously announced on July 21, 2022. 
生物技术迷幻药公司HAVN生命科学公司(场外交易代码:HAVLF)最近完成了与创新基金的首批融资协议阿尔法蓝海(《ABO》),此前于2022年7月21日宣布。
Since its creation in 2017, ABO has executed more than $1.5 billion in financial commitments and more than 90 ‎transactions, mostly within the life sciences sector, all around the globe.
自2017年成立以来,ABO已经执行了超过15亿美元的财务承诺以及90多笔‎交易,其中大部分是全球生命科学领域的交易。
Following the current first-tranche closing, HAVN issued to the investment fund managed by ABO "Global Corporate Finance Opportunities 17" a total $1,100,000 principal amount of senior unsecured convertible debenture as well as 189,393 common share purchase warrants for net proceeds of approximately $420,000.
在目前的第一批结束后,HAVN向ABO管理的投资基金《全球企业融资机会17》总计1,100,000美元的优先无担保可转换债券本金以及189,393份普通股认购权证,净收益约为420,000美元。
The convertible debenture may...
这个可转...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发